Omicron News and Research

RSS

Omicron's edge: boosters pressure SARS-CoV-2 to adapt and evolve

The effects of vaccine booster doses on the adaptive evolution of the virus.

25 Oct 2023

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Study investigates the receptor affinity and antigenicity of the SARS-CoV-2 Omicron BA.2.86 variant, revealing that it does not show higher resistance to neutralization by human sera than other recent variants. Despite its high number of mutations and receptor affinity, the variant is slightly more sensitive to neutralization than the EG.5.1 variant, warranting continued surveillance.

24 Oct 2023

Kids with Omicron non-infectious after three days, vaccination status irrelevant

Study found that the median duration of infectivity for the Omicron variant of SARS-CoV-2 in children is three days, regardless of vaccination status. The findings suggest that current 5-day isolation policies are supported, but vaccination or booster status need not be considered in return-to-school guidelines.

24 Oct 2023

Community immunity: Steering the evolutionary course of SARS-CoV-2

Researchers in Germany have developed a comprehensive fitness model that forecasts the evolution of SARS-CoV-2 by integrating genetic, epidemiological, and immunological data. The study emphasizes the role of population immunity in shaping viral mutations and provides valuable insights into the emergence of new variants.

24 Oct 2023

Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited.

24 Oct 2023

Research suggests shorter isolation periods for children with COVID-19

School policies that require students with COVID-19 to stay out of the classroom for five days are more than sufficient.

24 Oct 2023

Study reveals impact of hybrid immunity and booster vaccination on antibody waning

The decline in neutralizing antibody (nAb) titers following COVID-19 vaccination.

24 Oct 2023

Intranasal vaccination: A potent one-time solution for comprehensive COVID-19 immunity

A single-dose intranasal vaccine effectively induces robust immune responses.

24 Oct 2023

Assessing COVID-19 vaccine effectiveness against long COVID

Researchers discuss SARS-CoV-2 vaccine effectiveness in preventing long COVID in fully vaccinated individuals.

19 Oct 2023

Is it time to rethink COVID-19 boosters? New study dives into variant-specific vaccines

The study explores the efficacy of variant-adapted COVID-19 booster vaccines, particularly against new strains like Omicron. It raises questions about the need for annual updates and the best technologies for long-term, durable immunity.

15 Oct 2023

Pfizer Australia and BioNTech announce TGA approval for Omicron XBB.1.5-adapted monovalent COVID-19 vaccine

Pfizer Australia and BioNTech SE today announced that the Therapeutic Goods Administration (TGA) have authorised the companies’ XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) in individuals 5 years and older.

14 Oct 2023

New insights into coronavirus E channel could lead to antiviral drugs

The genome of the SARS-CoV-2 virus encodes 29 proteins, one of which is an ion channel called E. This channel, which transports protons and calcium ions, induces infected cells to launch an inflammatory response that damages tissues and contributes to the symptoms of Covid-19.

13 Oct 2023

Strong antibody response and nasal cytokines may protect young children from severe COVID-19

New research helps explain why young children have lower rates of severe COVID-19 than adults. A study of infants and young children found those who acquired SARS-CoV-2 had a strong, sustained antibody response to the virus and high levels of inflammatory proteins in the nose but not in the blood.

13 Oct 2023

Moderna's updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

Moderna's updated mRNA-1273.815 COVID-19 vaccine shows promising results in reducing symptomatic cases, hospitalizations, and deaths in high-risk and older adults in Germany. The study finds the vaccine to be more cost-effective and clinically beneficial than both no vaccination and Pfizer's XBB.1.5 BNT162b2 vaccine.

12 Oct 2023

EVScape: New tool to forecast which SARS-CoV-2 variants could dodge our immunity

Researchers have developed EVScape, a predictive tool that identifies which SARS-CoV-2 strains are most likely to evade host immunity. Utilizing a deep generative model and structural information, the tool offers early warning about viral variants, aiding in the timely development of effective vaccines and treatments.

12 Oct 2023

Next-gen intranasal vaccine takes on measles, mumps, and multiple COVID-19 variants in one shot

Researchers developed an intranasal trivalent measles-mumps-SARS-CoV-2 vaccine that provides robust protection against multiple coronavirus variants. Leveraging the established measles-mumps-rubella platform, this vaccine demonstrates broad and adaptable immune responses, especially against Delta and Omicron variants.

8 Oct 2023

Antigenic cartography decodes the mysteries of SARS-CoV-2 variants and vaccines

Using antigenic cartography, researchers analyzed cross-reactivity patterns of SARS-CoV-2 variants and the effect of spike-protein changes on post-infection and vaccination immune responses. The study illuminated unique neutralization profiles and underscored the evolving defense mechanisms with repeated immunizations.

8 Oct 2023

Novavax vaccine shows resilient defense against symptomatic COVID-19 despite Omicron challenge

Recent study assesses NVX-CoV2373 vaccine's effectiveness against Omicron variant. Findings show decreased efficacy over four months, but stable protection against symptomatic COVID-19.

8 Oct 2023

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment's efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.

8 Oct 2023

Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.

8 Oct 2023

Omicron News and Research

Omicron's edge: boosters pressure SARS-CoV-2 to adapt and evolve

BA.2.86 Omicron sub-variant shows high receptor affinity but moderate neutralization resistance

Kids with Omicron non-infectious after three days, vaccination status irrelevant

Community immunity: Steering the evolutionary course of SARS-CoV-2

Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Research suggests shorter isolation periods for children with COVID-19

Study reveals impact of hybrid immunity and booster vaccination on antibody waning

Intranasal vaccination: A potent one-time solution for comprehensive COVID-19 immunity

Assessing COVID-19 vaccine effectiveness against long COVID

Is it time to rethink COVID-19 boosters? New study dives into variant-specific vaccines

Pfizer Australia and BioNTech announce TGA approval for Omicron XBB.1.5-adapted monovalent COVID-19 vaccine

New insights into coronavirus E channel could lead to antiviral drugs

Strong antibody response and nasal cytokines may protect young children from severe COVID-19

Moderna's updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

EVScape: New tool to forecast which SARS-CoV-2 variants could dodge our immunity

Next-gen intranasal vaccine takes on measles, mumps, and multiple COVID-19 variants in one shot

Antigenic cartography decodes the mysteries of SARS-CoV-2 variants and vaccines

Novavax vaccine shows resilient defense against symptomatic COVID-19 despite Omicron challenge

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News